<DOC>
	<DOCNO>NCT03029741</DOCNO>
	<brief_summary>The Sponsor develop study drug , AZD0284 , potential treatment Plaque psoriasis . Psoriasis skin condition cause red , flaky , crusty patch skin cover silvery scale . It occur skin cell replace quickly usual . The seriousness psoriasis varies greatly person person . For people minor irritation , others major impact quality life . . The purpose study determine much AZD0284 take body . The safety tolerability drug also assess . It hop study drug improve management psoriasis .</brief_summary>
	<brief_title>Bioavailability AZD0284 IV Microtracer Study</brief_title>
	<detailed_description>The study Phase I , single centre , open-label , non-randomized , single dose study perform 6 healthy male subject age 18 65 year , inclusive . The study ass absolute bioavailability single oral dose AZD0284 pharmacokinetics ( PK ) single intravenous ( IV ) microdose [ 14C ] AZD0284 healthy male female subject . Oral AZD0284 [ 14C ] AZD0284 intravenous solution refer investigational product study . A screening visit ass eligibility healthy male female subject occur within 28 day administration investigational product . Screening assessment include medical history , inclusion/exclusion criterion , demographic data , weight height , vein assessment , physical examination , blood sample haematology , clinical chemistry virology , blood test confirm post-menopausal status ( female non-childbearing potential ) , blood test confirm history tuberculosis , urine sample urinalysis , urine test pregnancy ( female childbearing potential ) drug screen , alcohol breath test , carbon monoxide ( CO ) breath test , heart monitoring use ECG , vital sign ( blood pressure , heart rate ) Study related procedure perform sign Informed Consent Form . The healthy male female subject admit study centre day administration investigational product ( Day -1 ) . On Day 1 , subject dose single oral dose 4 120 mg AZD0284 oral suspension ( Regimen A ) follow 20 Î¼g [ 14C ] AZD0284 solution IV infusion ( Regimen B ) begin 3 hour oral dose administer . The IV microdose infuse 15 minute end infusion expect around predict tmax Regimen A . The subject remain study centre 48 hour post dose PK blood sample obtain . A follow visit occur 5 7 day dose include PK routine safety assessment .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Signed dated , write inform 2 . Healthy male nonpregnant , nonlactating healthy female . 3 . Age 18 65 year age . 4 . Suitable vein cannulation repeat venepuncture . 5 . Females must negative pregnancy test screen admission unit , must lactate must nonchildbearing potential , confirm screen fulfil 1 follow criterion : Postmenopausal define amenorrhoea least 12 month follow cessation exogenous hormonal treatment follicle stimulate hormone ( FSH ) level postmenopausal range . Documentation irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy tubal ligation . 6 . Body mass index 18.0 30.0 kg/m2 , inclusive , , outside range , consider clinically significant investigator , weigh least 50 kg 100 kg , inclusive . 7 . Must willing able communicate participate whole study . 8 . Must agree use adequate method contraception Exclusion 1 . History clinically significant disease disorder , opinion investigator , may either put volunteer risk participation study , influence result volunteer 's ability participate study . 2 . History presence gastrointestinal , hepatic renal disease , condition know interfere absorption , distribution , metabolism excretion drug . 3 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week first administration investigational medicinal product ( IMP ) . 4 . Subject increase risk infection History and/or presence tuberculosis ( TB ) positive result IFNy release assay ( IGRA ) ( ie QuantiFERON TBGold ) . The test may repeat initial test result indeterminate . Is highrisk group human immunodeficiency virus ( HIV ) infection within last 6 month . Subjects disease history suggest abnormal immune function judgement investigator . ( This include mild allergy childhood asthma eczema ) . 5 . Any clinically significant abnormality clinical chemistry , haematology urinalysis , judge investigator . 6 . Any clinically significant abnormal finding vital sign , judge investigator . 7 . Any clinically significant abnormal finding 12lead ECG , judge investigator . 8 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) HIV result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>